Search

Your search keyword '"Pandey, Ambarish"' showing total 73 results
Start Over Author "Pandey, Ambarish" Publisher wiley
73 results on '"Pandey, Ambarish"'

2. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial

Author

Pandey, Ambarish, primary, Patel, Kershaw V., additional, Segar, Matthew W., additional, Ayers, Colby, additional, Linge, Jennifer, additional, Leinhard, Olof D., additional, Anker, Stefan D., additional, Butler, Javed, additional, Verma, Subodh, additional, Joshi, Parag H., additional, and Neeland, Ian J., additional

Published
2024
Full Text
View/download PDF

3. Association of diabetes‐specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study

Author

Chunawala, Zainali S., primary, Keshvani, Neil, additional, Segar, Matthew W., additional, Patel, Kershaw V., additional, Usman, Muhammad Shariq, additional, Subramanian, Vinayak, additional, Raygor, Viraj, additional, Chandra, Alvin, additional, Khan, Muhammad Shahzeb, additional, and Pandey, Ambarish, additional

Published
2024
Full Text
View/download PDF

5. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial

Author

Pandey, Ambarish, Patel, Kershaw V., Segar, Matthew W., Ayers, Colby, Linge, Jennifer, Dahlqvist Leinhard, Olof, Anker, Stefan D., Butler, Javed, Verma, Subodh, Joshi, Parag H., Neeland, Ian J., Pandey, Ambarish, Patel, Kershaw V., Segar, Matthew W., Ayers, Colby, Linge, Jennifer, Dahlqvist Leinhard, Olof, Anker, Stefan D., Butler, Javed, Verma, Subodh, Joshi, Parag H., and Neeland, Ian J.

Abstract

BackgroundExcess muscle fat is observed in obesity and associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat and adverse muscle composition is unknown.MethodsThis is a pre-specified secondary analysis of a randomized, double-blind, placebo-controlled trial that examined the effects of liraglutide plus a lifestyle intervention on visceral adipose tissue and ectopic fat among adults without diabetes with body mass index >= 30 kg/m2 or >= 27 kg/m2 and metabolic syndrome. Participants were randomly assigned to a once-daily subcutaneous injection of liraglutide (target dose 3.0 mg) or matching placebo for 40 weeks. Body fat distribution and muscle composition was assessed by magnetic resonance imaging at baseline and 40-week follow-up. Muscle composition was described by the combination of thigh muscle fat and muscle volume. Treatment difference (95% confidence intervals [CI]) was calculated by least-square means adjusted for baseline thigh muscle fat. The association between changes in thigh muscle fat and changes in body weight were assessed using Spearman correlation coefficients. The effect of liraglutide versus placebo on adverse muscle composition, denoted by high thigh muscle fat and low thigh muscle volume, was explored.ResultsAmong the 128 participants with follow-up imaging (92.2% women, 36.7% Black), median muscle fat at baseline was 7.8%. The mean percent change in thigh muscle fat over median follow-up of 36 weeks was -2.87% among participants randomized to liraglutide (n = 73) and 0.05% in the placebo group (absolute change: -0.23% vs. 0.01%). The estimated treatment difference adjusted for baseline thigh muscle fat was -0.24% (95% CI, -0.41 to -0.06, P-value 0.009). Longitudinal change in thigh muscle fat was significantly associated with change in body weight in the placebo group but not the liraglutide group. The proport, Funding Agencies|Novo Nordisk

Published
2024
Full Text
View/download PDF

9. Sex differences in long‐term outcomes following acute heart failure hospitalization: Findings from the Get With The Guidelines‐Heart Failure registry

Author

Keshvani, Neil, primary, Shah, Sonia, additional, Ayodele, Iyanuoluwa, additional, Chiswell, Karen, additional, Alhanti, Brooke, additional, Allen, Larry A., additional, Greene, Stephen J., additional, Yancy, Clyde W., additional, Alonso, Windy W., additional, Van Spall, Harriette GC, additional, Fonarow, Gregg C., additional, Heidenreich, Paul A., additional, and Pandey, Ambarish, additional

Published
2023
Full Text
View/download PDF

12. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society

Author

Tsutsui, Hiroyuki, primary, Albert, Nancy M., additional, Coats, Andrew J.S., additional, Anker, Stefan D., additional, Bayes‐Genis, Antoni, additional, Butler, Javed, additional, Chioncel, Ovidiu, additional, Defilippi, Christopher R., additional, Drazner, Mark H., additional, Felker, G. Michael, additional, Filippatos, Gerasimos, additional, Fiuzat, Mona, additional, Ide, Tomomi, additional, Januzzi, James L., additional, Kinugawa, Koichiro, additional, Kuwahara, Koichiro, additional, Matsue, Yuya, additional, Mentz, Robert J., additional, Metra, Marco, additional, Pandey, Ambarish, additional, Rosano, Giuseppe, additional, Saito, Yoshihiko, additional, Sakata, Yasushi, additional, Sato, Naoki, additional, Seferovic, Petar M., additional, Teerlink, John, additional, Yamamoto, Kazuhiro, additional, and Yoshimura, Michihiro, additional

Published
2023
Full Text
View/download PDF

15. Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus

Author

Segar, Matthew W., primary, Kolkailah, Ahmed A., additional, Frederich, Robert, additional, Pong, Annpey, additional, Cannon, Christopher P., additional, Cosentino, Francesco, additional, Dagogo‐Jack, Samuel, additional, McGuire, Darren K., additional, Pratley, Richard E., additional, Liu, Chih‐Chin, additional, Maldonado, Mario, additional, Liu, Jie, additional, Cater, Nilo B., additional, Pandey, Ambarish, additional, and Cherney, David Z. I., additional

Published
2022
Full Text
View/download PDF

16. Heart failure quality of care and in‐hospital outcomes during the COVID ‐19 pandemic: findings from the Get With The Guidelines‐Heart Failure registry

Author

Keshvani, Neil, primary, Mehta, Anurag, additional, Alger, Heather M., additional, Rutan, Christine, additional, Williams, Joseph, additional, Zhang, Shuiaqi, additional, Young, Rebecca, additional, Alhanti, Brooke, additional, Chiswell, Karen, additional, Greene, Stephen J., additional, DeVore, Adam D., additional, Yancy, Clyde W., additional, Fonarow, Gregg C., additional, and Pandey, Ambarish, additional

Published
2022
Full Text
View/download PDF

19. Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia

Author

Segar, Matthew W., primary, Khan, Muhammad Shahzeb, additional, Patel, Kershaw V., additional, Vaduganathan, Muthiah, additional, Kannan, Vaishnavi, additional, Willett, Duwayne, additional, Peterson, Eric, additional, Tang, W.H. Wilson, additional, Butler, Javed, additional, Everett, Brendan M., additional, Fonarow, Gregg C., additional, Wang, Thomas J., additional, McGuire, Darren K., additional, and Pandey, Ambarish, additional

Published
2021
Full Text
View/download PDF

27. Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT

Author

Peters, Anthony E., primary, Pandey, Ambarish, additional, Ayers, Colby, additional, Wegermann, Kara, additional, McGarrah, Robert W., additional, Grodin, Justin L., additional, Abdelmalek, Manal F., additional, Bekfani, Tarek, additional, Blumer, Vanessa, additional, Diehl, Anna Mae, additional, Moylan, Cynthia A., additional, and Fudim, Marat, additional

Published
2021
Full Text
View/download PDF

35. Wake Forest University long‐term follow‐up of type 2 myocardial infarction: The Wake‐Up T2MI Registry

Author

Jogu, Hanumantha R., primary, Arora, Sameer, additional, Vaduganathan, Muthiah, additional, Qamar, Arman, additional, Pandey, Ambarish, additional, Chevli, Parag A., additional, Pansuriya, Tusharkumar H., additional, Ahmad, Muhammad I., additional, Dutta, Abhishek, additional, Sunkara, Padageshwar R., additional, Qureshi, Waqas, additional, Vasu, Sujethra, additional, Upadhya, Bharathi, additional, Bhatt, Deepak L., additional, Januzzi, James L., additional, and Herrington, David, additional

Published
2019
Full Text
View/download PDF

47. Development and validation of a machine learning-based approach to identify high-risk diabetic cardiomyopathy phenotype.

Author

Segar MW, Usman MS, Patel KV, Khan MS, Butler J, Manjunath L, Lam CSP, Verma S, Willett D, Kao D, Januzzi JL, and Pandey A

Abstract

Aims: Abnormalities in specific echocardiographic parameters and cardiac biomarkers have been reported among individuals with diabetes. However, a comprehensive characterization of diabetic cardiomyopathy (DbCM), a subclinical stage of myocardial abnormalities that precede the development of clinical heart failure (HF), is lacking. In this study, we developed and validated a machine learning-based clustering approach to identify the high-risk DbCM phenotype based on echocardiographic and cardiac biomarker parameters., Methods and Results: Among individuals with diabetes from the Atherosclerosis Risk in Communities (ARIC) cohort who were free of cardiovascular disease and other potential aetiologies of cardiomyopathy (training, n = 1199), unsupervised hierarchical clustering was performed using echocardiographic parameters and cardiac biomarkers of neurohormonal stress and chronic myocardial injury (total 25 variables). The high-risk DbCM phenotype was identified based on the incidence of HF on follow-up. A deep neural network (DeepNN) classifier was developed to predict DbCM in the ARIC training cohort and validated in an external community-based cohort (Cardiovascular Health Study [CHS]; n = 802) and an electronic health record (EHR) cohort (n = 5071). Clustering identified three phenogroups in the derivation cohort. Phenogroup-3 (n = 324, 27% of the cohort) had significantly higher 5-year HF incidence than other phenogroups (12.1% vs. 4.6% [phenogroup 2] vs. 3.1% [phenogroup 1]) and was identified as the high-risk DbCM phenotype. The key echocardiographic predictors of high-risk DbCM phenotype were higher NT-proBNP levels, increased left ventricular mass and left atrial size, and worse diastolic function. In the CHS and University of Texas (UT) Southwestern EHR validation cohorts, the DeepNN classifier identified 16% and 29% of participants with DbCM, respectively. Participants with (vs. without) high-risk DbCM phenotype in the external validation cohorts had a significantly higher incidence of HF (hazard ratio [95% confidence interval] 1.61 [1.18-2.19] in CHS and 1.34 [1.08-1.65] in the UT Southwestern EHR cohort)., Conclusion: Machine learning-based techniques may identify 16% to 29% of individuals with diabetes as having a high-risk DbCM phenotype who may benefit from more aggressive implementation of HF preventive strategies., (© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

48. A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial.

Author

Kitzman DW, Lewis GD, Pandey A, Borlaug BA, Sauer AJ, Litwin SE, Sharma K, Jorkasky DK, Khan S, and Shah SJ

Abstract

Aims: Compared with those without obesity, patients with obesity-related heart failure with preserved ejection fraction (HFpEF) have worse symptoms, haemodynamics, and outcomes. Current weight loss strategies (diet, drug, and surgical) work through decreased energy intake rather than increased expenditure and cause significant loss of skeletal muscle mass in addition to adipose tissue. This may have adverse implications for patients with HFpEF, who already have reduced skeletal muscle mass and function and high rates of physical frailty. Mitochondrial uncoupling agents may have unique beneficial effects by producing weight loss via increased catabolism rather than reduced caloric intake, thereby causing loss of adipose tissue while sparing skeletal muscle. HU6 is a controlled metabolic accelerator that is metabolized to the mitochondrial uncoupling agent 2,4-dinotrophenol. HU6 selectively increases carbon oxidation from fat and glucose while also decreasing toxic reactive oxygen species (ROS) production. In addition to sparing skeletal muscle loss, HU6 may have other benefits relevant to obesity-related HFpEF, including reduced specific tissue depots contributing to HFpEF; improved glucose utilization; and reduction in systemic inflammation via both decreased ROS production from mitochondria and decreased cytokine elaboration from excess, dysfunctional adipose., Methods: We describe the rationale and design of HuMAIN-HFpEF, a Phase 2a randomized, double-blind, placebo-controlled, dose-titration, parallel-group trial in patients with obesity-related HFpEF to evaluate the effects of HU6 on weight loss, body composition, exercise capacity, cardiac structure and function, metabolism, and inflammation, and identify optimal dosage for future Phase 3 trials., Conclusions: HuMAIN will test a promising novel agent for obesity-related HFpEF., (© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

49. Association of global longitudinal strain by feature tracking cardiac magnetic resonance imaging with adverse outcomes among community-dwelling adults without cardiovascular disease: The Dallas Heart Study.

Author

Subramanian V, Keshvani N, Segar MW, Kondamudi NJ, Chandra A, Maddineni B, Matulevicius SA, Michos ED, Lima JAC, Berry JD, and Pandey A

Subjects
Adult, Humans, Male, Female, Global Longitudinal Strain, Independent Living, Magnetic Resonance Imaging, Cine methods, Ventricular Function, Left, Magnetic Resonance Imaging, Stroke Volume, Prognosis, Biomarkers, Predictive Value of Tests, Cardiovascular Diseases epidemiology, Heart Failure epidemiology
Abstract

Aim: Left ventricular (LV) global longitudinal strain (GLS) may detect subtle abnormalities in myocardial contractility among individuals with normal LV ejection fraction (LVEF). However, the prognostic implications of GLS among healthy, community-dwelling adults is not well-established., Methods and Results: Overall, 2234 community-dwelling adults (56% women, 47% Black) with LVEF ≥50% without a history of cardiovascular disease (CVD) from the Dallas Heart Study who underwent cardiac magnetic resonance (CMR) with GLS assessed by feature tracking CMR (FT-CMR) were included. The association of GLS with the risk of incident major adverse cardiovascular events (MACE; composite of incident myocardial infarction, incident heart failure [HF], hospitalization for atrial fibrillation, coronary revascularization, and all-cause death), and incident HF or death were assessed with adjusted Cox proportional hazards models. A total of 309 participants (13.8%) had MACE during a median follow-up duration of 17 years. Participants with the worst GLS (Q4) were more likely male and of the Black race with a history of tobacco use and diabetes with lower LVEF, higher LV end-diastolic volume, and higher LV mass index. Cumulative incidence of MACE was higher among participants with worse (Q4 vs. Q1) GLS (20.4% vs. 9.0%). In multivariable-adjusted Cox models that included clinical characteristics, cardiac biomarkers and baseline LVEF, worse GLS (Q4 vs. Q1) was associated with a significantly higher risk of MACE (hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.07-2.24, p = 0.02) and incident HF or death (HR 1.57, 95% CI 1.03-2.38, p = 0.04)., Conclusions: Impaired LV GLS assessed by FT-CMR among adults free of cardiovascular disease is associated with a higher risk of incident MACE and incident HF or death independent of cardiovascular risk factors, cardiac biomarkers and LVEF., (© 2024 European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

50. Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial.

Author

Patel KV, Khan MS, Segar MW, Bahnson JL, Garcia KR, Clark JM, Balasubramanyam A, Bertoni AG, Vaduganathan M, Farkouh ME, Januzzi JL Jr, Verma S, Espeland M, and Pandey A

Subjects
Humans, Stroke Volume, Heart Failure epidemiology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 epidemiology
Abstract

Aims: To evaluate the contribution of baseline and longitudinal changes in cardiometabolic health (CMH) towards heart failure (HF) risk among adults with type 2 diabetes (T2D)., Methods and Results: Participants of the Look AHEAD trial with T2D and without prevalent HF were included. Adjusted Cox models were used to create a CMH score incorporating target levels of parameters weighted based on relative risk for HF. The associations of baseline and changes in the CMH score with risk of overall HF, HF with preserved (HFpEF) and reduced ejection fraction (HFrEF) were assessed using Cox models. Among the 5080 participants, 257 incident HF events occurred over 12.4 years of follow-up. The CMH score included 2 points each for target levels of waist circumference, glomerular filtration rate, urine albumin-to-creatinine ratio, and 1 point each for blood pressure and glycated haemoglobin at target. High baseline CMH score (6-8) was significantly associated with lower overall HF risk (adjusted hazard ratio [HR], ref = low score (0-3): 0.31, 95% confidence interval [CI] 0.21-0.47) with similar associations observed for HFpEF and HFrEF. Improvement in CMH was significantly associated with lower risk of overall HF (adjusted HR per 1-unit increase in score at 4 years: 0.80, 95% CI 0.70-0.91). In the ACCORD validation cohort, the baseline CMH score performed well for predicting HF risk with adequate discrimination (C-index 0.70), calibration (chi-square 5.53, p = 0.70), and risk stratification (adjusted HR [high (6-8) vs. low score (0-3)]: 0.35, 95% CI 0.26-0.46). In the Look AHEAD subgroup with available biomarker data, incorporating N-terminal pro-B-type natriuretic peptide to the baseline CMH score improved model discrimination (C-index 0.79) and risk stratification (adjusted HR [high (8-10) vs. low score (0-4)]: 0.18, 95% CI 0.09-0.35)., Conclusions: Achieving target levels of more CMH parameters at baseline and sustained improvements were associated with lower HF risk in T2D., (© 2022 European Society of Cardiology.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results